Item(by='fsh', descendants=None, kids=None, score=None, time=1609345476, title=None, item_type='comment', url=None, parent=25580277, text='None of the 18860 participants of the Phase 2&#x2F;3 trial reported allergic reactions after either dose of the vaccine [1]. Over the entire duration of the study, one member of the treatement group suffered an anaphylactic reaction and one member of the placebo group an anaphylactic shock [2]. There is no hint that this particular vaccine is more likely to trigger allergic reactions than any other kind of medication.<p>[1] Section 6.3.3.2.2.1. in <a href="https:&#x2F;&#x2F;www.fda.gov&#x2F;media&#x2F;144246&#x2F;download" rel="nofollow">https:&#x2F;&#x2F;www.fda.gov&#x2F;media&#x2F;144246&#x2F;download</a><p>[2] Table 23, Ibid.')